Galantide

• Description :

  Galantide, a non-specific galanin receptor antagonist, is a peptide consisting of fragments of galanin and substance P. Galantide recognizes two classes of galanin binding sites (KD50=1.0 nM) antagonizes the galanin-mediated inhibition of the glucose-induced insulin secretion from mouse pancreatic islets. Galantide appears to bind to a single population of SP receptors (KD~40 nM) [1][2][3].

• CAS Number :

  [138579-66-5]

• UNSPSC :

  12352209

• Target :

  Neuropeptide Y Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Metabolic Disease; Inflammation/Immunology; Neurological Disease; Endocrinology

• Assay Protocol :

  https://www.medchemexpress.com/Galantide.html

• Solubility :

  10 mM in DMSO

• Smiles :

  OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(NCC(N2[C@@H](CCC2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@H](C(NCC(N[C@@H](CC(C)C)C(N[C@H](C(N)=O)CCSC)=O)=O)=O)CC3=CC=CC=C3)=O)CC4=CC=CC=C4)=O)=O)=O)=O)=O)=O)=O)NC(CNC([C@H](C)NC([C@H](CO)NC([C@H](CC(N)=O)NC([C@H](CC(C)C)NC([C@H]([C@H](O)C)NC([C@@H](NC(CN)=O)CC5=CNC6=CC=CC=C56)=O)=O)=O)=O)=O)=O)=O

• Molecular Formula :

  C104H151N25O26S

• Molecular Weight :

  2199.53

• References & Citations :

  [1]Langel U, et al. Design of chimeric peptide ligands to galanin receptors and substance P receptors. Int J Pept Protein Res. 1992;39 (6) :516-522.|[2]Lindskog S, et al. The novel high-affinity antagonist, galantide, blocks the galanin-mediated inhibition of glucose-induced insulin secretion. Eur J Pharmacol. 1992;210 (2) :183-188.|[3]Mulvaney JM, et al. Galantide distinguishes putative subtypes of galanin receptors in mudpuppy parasympathetic neurons. Eur J Pharmacol. 1995;287 (1) :97-100.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported